Recap of News Today
Bio-Path Holdings Reveals Interim Results From Phase 2 Study Of Prexigebersen In Combination With Decitabine And Venetoclax For Treatment Of Acute Myeloid Leukemia
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for treating acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress.
Dr. Jorge Cortes presented data showing the combination therapy was well-tolerated and demonstrated significant clinical improvements. In Cohort 1, 75% of evaluable newly diagnosed AML patients achieved complete remission (CR), CR with partial recovery (CRh), or CR with incomplete hematologic recovery (CRi). In Cohort 2, 55% of evaluable relapsed/refractory AML patients achieved CR/CRi/CRh. Adverse events included fatigue, anemia, and neutropenia, with severe events like febrile neutropenia and sepsis. Bio-Path plans to continue enrolling up to 98 and 54 patients for Cohorts 1 and 2 respectively.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1076Followers
68Following
7422Visitors
Follow